Sanofi American Depositary Shares (Each repstg one-half of one)

This stock has a reasonable momentum. Sanofi American Depositary Shares (Each repstg one-half of one) is not a good growth stock. Sanofi American Depositary Shares (Each repstg one-half of one) is a mediocre stock to choose.
Log in to see more information.
Sanofi engages in the research, production and distribution of pharmaceutical products. It operates...
SNY Fundamental Data by TradingView

News

Sanofi in licensing deal for radiopharmaceutical for cancer
Sanofi in licensing deal for radiopharmaceutical for cancer

SeekingAlpha.com: All News Sanofi signs exclusive licensing deal for AlphaMedix radioligand treatment for rare cancer neuroendocrine tumors. Read more here.\n more…

Sanofi (NASDAQ:SNY) Shares Bought by Wedbush Securities Inc.
Sanofi (NASDAQ:SNY) Shares Bought by Wedbush Securities Inc.

Zolmax Wedbush Securities Inc. raised its holdings in shares of Sanofi (NASDAQ:SNY - Free Report) by 32.9% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The...\n more…

Sanofi pays $110M upfront for late-stage radioligand therapy, setting up rivalry with Novartis
Sanofi pays $110M upfront for late-stage radioligand therapy, setting up rivalry with Novartis

FierceBiotech.com - Biotech Sanofi pays $110M upfront for late-stage radioligand therapy, setting up rivalry with Novartis\nntaylor\nThu, 09/12/2024 - 04:55...\n more…

Sanofi (NASDAQ:SNY) Cut to Buy at StockNews.com
Sanofi (NASDAQ:SNY) Cut to Buy at StockNews.com

Ticker Report StockNews.com cut shares of Sanofi (NASDAQ:SNY - Free Report) from a strong-buy rating to a buy rating in a report released on Wednesday morning. Separately, Argus boosted their price target on...\n more…

Sanofi (NASDAQ:SNY) Downgraded to "Buy" at StockNews.com
Sanofi (NASDAQ:SNY) Downgraded to "Buy" at StockNews.com

Zolmax StockNews.com lowered shares of Sanofi (NASDAQ:SNY - Free Report) from a strong-buy rating to a buy rating in a research report sent to investors on Wednesday.\nSeparately, Argus lifted their target...\n more…

Press Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers
Press Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers

Globe Newswire Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers Paris, France, and Houston, Texas, September 12, 2024. As part of its...\n more…